Author response to: Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study

S K Kamarajah^{1

2}, S R Markar³

Affiliations

¹ Department of Upper Gastrointestinal Surgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Trust, Birmingham, UK.
² Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
³ Department of Surgery & Cancer, Imperial College London, London, UK.

Comment

S K Kamarajah et al. Br J Surg. 2021.

. 2021 Aug 19;108(8):e279.

doi: 10.1093/bjs/znab154.

S K Kamarajah^{1

2}, S R Markar³

¹ Department of Upper Gastrointestinal Surgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Trust, Birmingham, UK.
² Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
³ Department of Surgery & Cancer, Imperial College London, London, UK.

No abstract available

Comment on

Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK, Phillips AW, Ferri L, Hofstetter WL, Markar SR. Kamarajah SK, et al. Br J Surg. 2021 Apr 30;108(4):403-411. doi: 10.1093/bjs/znaa121. Br J Surg. 2021. PMID: 33755097
Comment on: Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Deng HY. Deng HY. Br J Surg. 2021 Aug 19;108(8):e278. doi: 10.1093/bjs/znab153. Br J Surg. 2021. PMID: 34412119 No abstract available.

1. Kamarajah SK, Phillips AW, Ferri L, Hofstetter WL, Markar SR.. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study. Br J Surg 2021;108:403–411. - PubMed